Computer-controlled sedation could lighten the load for intensive-care staff and make the process safer for patients.
A startup will sift through “treasure troves” of data from failed trials to find abandoned Alzheimer’s drugs that might work for some patients.
The U.K. plans to sequence 100,000 National Health Service patients by 2017—in a bold push to be a genomic medicine leader.
The newest cancer drugs cost over $100,000 for a year of treatment. There are fairer ways to set prices.
Today’s medicines can cost hundreds of thousands of dollars a year. The story of how two companies set prices for their costly new drugs suggests that the way we determine the value of such treatments will help decide the future of our health-care system.
Biotech startup Greenlight Biosciences has a cell-free approach to microbial chemical production.
Scientists use immune cells to smuggle molecules across the blood-brain barrier in the hopes of treating neurodegenerative diseases.
World’s largest smartphone chipmaker offers to custom-build very efficient neuro-inspired chips for phones, robots, and vision systems.
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Despite promising results in controlling neuronal activity, leaders in brain research still wrestle over turning their work into treatments.